Welcome to our dedicated page for Harvard Biosci news (Ticker: HBIO), a resource for investors and traders seeking the latest updates and insights on Harvard Biosci stock.
Harvard Bioscience reports company news on its life science research tools business, which develops, manufactures and sells technologies, products and services for research, pharmaceutical and therapy discovery, bioproduction and preclinical testing. Updates commonly cover operating and financial results, new products for translational science, New Approach Methodologies, product mix, and customer markets that include academic institutions, government laboratories, pharmaceutical companies, biotechnology companies and contract research organizations.
Company releases also address capital actions, Nasdaq listing compliance, manufacturing and operating-model changes, management appointments, guidance, and investor conference presentations. The business sells through direct and distribution channels and has operations in the United States, Europe and China.
Harvard Bioscience (Nasdaq: HBIO) reported second quarter 2026 revenue of $22.7 million, up 11% year over year (about 1% from FX), with gross profit of $12.6 million and gross margin of 55.6% versus 56.4% a year ago. Adjusted gross margin was 56.7%. Net loss widened to $2.9 million, while adjusted EBITDA increased to $1.7 million from $1.5 million.
For the first half of 2026, revenue rose to $43.5 million, net loss narrowed to $6.3 million from $52.6 million (which included a $48 million goodwill impairment in 2025), and adjusted EBITDA was $2.4 million. The company raised its full-year 2026 revenue growth outlook to 3%–5% and now targets adjusted gross margin of 57%–59% and adjusted EBITDA growth of 6%–10%. Third quarter 2026 guidance calls for revenue of $21.0–$22.6 million and adjusted EBITDA of $1.5–$2.5 million.
Harvard Bioscience (Nasdaq: HBIO) will release its financial results for the quarter ended June 30, 2026 before the market opens on August 11, 2026. The company will host an earnings conference call at 8:00 a.m. Eastern Time the same day to discuss the results.
Analysts who wish to ask questions must register in advance to receive dial-in details and a unique PIN. Other participants can access an audio-only webcast via the events and presentations section of the investor website. The earnings release, financial information and slide presentation will be available in the Investor Relations section of Harvard Bioscience’s website.
Harvard Bioscience (Nasdaq: HBIO) reported Q1 2026 revenue of $20.8M, down from $21.8M in Q1 2025, with gross margin improving to 59% from 56%.
Net loss narrowed to $3.4M from $50.3M, adjusted EBITDA was $0.8M, and full-year 2026 guidance was reaffirmed.
Harvard Bioscience (NASDAQ: HBIO) announced that CEO John Duke and CFO Mark Frost will participate in two virtual investor events in May 2026: a Sidoti Micro Cap Conference fireside chat on May 21, 2026 at 11:30 AM ET and a Benchmark (StoneX) Healthcare House Call on May 28, 2026.
According to the company, the Sidoti session will be webcast live on Harvard Bioscience’s investor relations website and an archived replay will be available after the event.
Harvard Bioscience (Nasdaq: HBIO) will report financial results for the quarter ended March 31, 2026 before market open on May 12, 2026 and will host a conference call at 8:00 AM ET the same day to discuss results.
Registration is required for analysts who wish to ask questions; an audio-only webcast will be available via the company investor website. Earnings release and slide presentation will be posted in Investor Relations.
Harvard Bioscience (Nasdaq: HBIO) reported Q4 2025 revenue $23.7M and full-year 2025 revenue $86.6M with gross margins of 59.7% (Q4) and 57.7% (FY). The company posted a $56.7M net loss in 2025, driven largely by a $48.0M goodwill impairment, and reported Adjusted EBITDA $8.1M for 2025. Mark Frost was named permanent CFO. Management issued 2026 guidance: Q1 revenue $20.0M–$22.0M and full-year revenue growth of 2%–4%, with adjusted gross margin 58%–60% and adjusted EBITDA growth 6%–10%.
Harvard Bioscience (NASDAQ: HBIO) announced a 1-for-10 reverse stock split approved March 6, 2026, effective 4:30 p.m. ET on March 13, 2026, with post-split trading expected March 16, 2026.
The Reverse Split will convert every ten shares into one, reduce outstanding shares from ~44,719,894 to ~4,471,989, leave total authorized shares unchanged, and proportionally adjust options, warrants, and convertible securities.
No fractional shares will be issued; fractional holders will receive cash in lieu based on the March 13, 2026 closing price as adjusted for the split.
Harvard Bioscience (Nasdaq: HBIO) announced that CEO John Duke and Interim CFO Mark Frost will participate in KeyBanc Capital Markets’ Virtual Healthcare Forum on Tuesday, March 17, 2026.
A fireside chat will be broadcast from the company’s investor relations website at 2:15pm ET, with an audio-only webcast option available via the events and presentations section.
Harvard Bioscience (Nasdaq: HBIO) will announce financial results for the quarter ended December 31, 2025 before the market opens on March 12, 2026.
The company will host an earnings conference call at 8:00 AM Eastern Time; registration is required for participants who wish to ask questions and an audio-only webcast will be available on the investor website.
Harvard Bioscience (NASDAQ: HBIO) reported preliminary Q4 2025 results and outlined a long-term translational science strategy. Q4 revenue $23.7M (above midpoint), gross margin 60% (high end) and adjusted EBITDA $3.8M (+27% YoY). The company targets year‑over‑year revenue growth and mid‑to‑high single‑digit EBITDA growth in 2026 while prioritizing new high‑margin platforms, consumables expansion (55% recurring mix) and operational consolidation, supported by recent debt refinancing and U.S. manufacturing consolidation. Full FY2025 results and a conference call are scheduled for March 12, 2026.